Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development.

Tagle DA.

Curr Opin Pharmacol. 2019 Oct;48:146-154. doi: 10.1016/j.coph.2019.09.007. Epub 2019 Oct 14. Review.

PMID:
31622895
2.

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development.

Wright CB, Becker SM, Low LA, Tagle DA, Sieving PA.

J Ocul Pharmacol Ther. 2019 Jun 5. doi: 10.1089/jop.2018.0139. [Epub ahead of print]

PMID:
31166829
3.

Mapping biologically active chemical space to accelerate drug discovery.

Sittampalam GS, Rudnicki DD, Tagle DA, Simeonov A, Austin CP.

Nat Rev Drug Discov. 2019 Feb;18(2):83-84. doi: 10.1038/d41573-018-00007-2. No abstract available.

PMID:
30710133
4.

Correction for Han et al., "Biochemical and Structural Properties of Mouse Kynurenine Aminotransferase III".

Han Q, Robinson H, Cai T, Tagle DA, Li J.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00099-18. doi: 10.1128/MCB.00099-18. Print 2018 May 15. No abstract available.

5.

Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research.

Low LA, Tagle DA.

Adv Exp Med Biol. 2017;1031:405-415. doi: 10.1007/978-3-319-67144-4_23. Review.

PMID:
29214585
6.

Tissue chips - innovative tools for drug development and disease modeling.

Low LA, Tagle DA.

Lab Chip. 2017 Sep 12;17(18):3026-3036. doi: 10.1039/c7lc00462a. Review.

7.

Organs-on-chips: Progress, challenges, and future directions.

Low LA, Tagle DA.

Exp Biol Med (Maywood). 2017 Oct;242(16):1573-1578. doi: 10.1177/1535370217700523. Epub 2017 Mar 26.

8.

Microphysiological Systems ("Organs-on-Chips") for Drug Efficacy and Toxicity Testing.

Low LA, Tagle DA.

Clin Transl Sci. 2017 Jul;10(4):237-239. doi: 10.1111/cts.12444. Epub 2017 Mar 7. No abstract available.

9.
10.

Diagnostic potential of extracellular RNA from biofluids.

Lombo TB, Ganguly A, Tagle DA.

Expert Rev Mol Diagn. 2016 Nov;16(11):1135-1138. Epub 2016 Oct 8. No abstract available.

PMID:
27682891
11.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A.

ALTEX. 2016;33(3):272-321. doi: 10.14573/altex.1603161. Epub 2016 May 15. Review.

12.

Tissue Chips to aid drug development and modeling for rare diseases.

Low LA, Tagle DA.

Expert Opin Orphan Drugs. 2016;4(11):1113-1121. doi: 10.1080/21678707.2016.1244479. Epub 2016 Oct 19.

13.

The NIH Extracellular RNA Communication Consortium.

Ainsztein AM, Brooks PJ, Dugan VG, Ganguly A, Guo M, Howcroft TK, Kelley CA, Kuo LS, Labosky PA, Lenzi R, McKie GA, Mohla S, Procaccini D, Reilly M, Satterlee JS, Srinivas PR, Church ES, Sutherland M, Tagle DA, Tucker JM, Venkatachalam S.

J Extracell Vesicles. 2015 Aug 28;4:27493. doi: 10.3402/jev.v4.27493. eCollection 2015.

14.

Perspectives on best practices for gene therapy programs.

Cheever TR, Berkley D, Braun S, Brown RH, Byrne BJ, Chamberlain JS, Cwik V, Duan D, Federoff HJ, High KA, Kaspar BK, Klinger KW, Larkindale J, Lincecum J, Mavilio F, McDonald CL, McLaughlin J, Weiss McLeod B, Mendell JR, Nuckolls G, Stedman HH, Tagle DA, Vandenberghe LH, Wang H, Wernett PJ, Wilson JM, Porter JD, Gubitz AK.

Hum Gene Ther. 2015 Mar;26(3):127-33. doi: 10.1089/hum.2014.147. Epub 2015 Mar 3.

15.

Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue.

Fabre KM, Livingston C, Tagle DA.

Exp Biol Med (Maywood). 2014 Sep;239(9):1073-7. doi: 10.1177/1535370214538916. Epub 2014 Jun 24. Review. No abstract available.

PMID:
24962171
16.

Expanding rare disease drug trials based on shared molecular etiology.

Brooks PJ, Tagle DA, Groft S.

Nat Biotechnol. 2014 Jun;32(6):515-8. doi: 10.1038/nbt.2924. No abstract available.

17.

Phenylketonuria Scientific Review Conference: state of the science and future research needs.

Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM.

Mol Genet Metab. 2014 Jun;112(2):87-122. doi: 10.1016/j.ymgme.2014.02.013. Epub 2014 Mar 6.

PMID:
24667081
18.

The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.

Sutherland ML, Fabre KM, Tagle DA.

Stem Cell Res Ther. 2013;4 Suppl 1:I1. doi: 10.1186/scrt361. Epub 2013 Dec 20.

19.

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.

Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH.

Hum Mol Genet. 2011 Apr 1;20(7):1438-55. doi: 10.1093/hmg/ddr024. Epub 2011 Jan 21.

20.
21.

Thermal stability, pH dependence and inhibition of four murine kynurenine aminotransferases.

Han Q, Cai T, Tagle DA, Li J.

BMC Biochem. 2010 May 19;11:19. doi: 10.1186/1471-2091-11-19.

22.

Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Han Q, Cai T, Tagle DA, Li J.

Cell Mol Life Sci. 2010 Feb;67(3):353-68. doi: 10.1007/s00018-009-0166-4. Epub 2009 Oct 15. Review.

23.

Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.

Han Q, Robinson H, Cai T, Tagle DA, Li J.

J Med Chem. 2009 May 14;52(9):2786-93. doi: 10.1021/jm9000874.

24.

Biochemical and structural properties of mouse kynurenine aminotransferase III.

Han Q, Robinson H, Cai T, Tagle DA, Li J.

Mol Cell Biol. 2009 Feb;29(3):784-93. doi: 10.1128/MCB.01272-08. Epub 2008 Nov 24. Erratum in: Mol Cell Biol. 2018 Apr 30;38(10 ):.

25.

Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II.

Han Q, Cai T, Tagle DA, Robinson H, Li J.

Biosci Rep. 2008 Aug;28(4):205-15. doi: 10.1042/BSR20080085.

26.

Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family.

Yu P, Li Z, Zhang L, Tagle DA, Cai T.

Gene. 2006 Jan 3;365:111-8. Epub 2006 Jan 10.

PMID:
16376499
27.

Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.

Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R.

Exp Neurol. 2006 Jan;197(1):31-40. Epub 2005 Aug 15.

PMID:
16099455
28.

Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements.

DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA.

J Neurocytol. 2004 Sep;33(5):517-33.

PMID:
15906159
29.

Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders.

Pearce DA, Atkinson M, Tagle DA.

Neurology. 2004 Dec 14;63(11):2001-5. Review.

PMID:
15596740
30.

Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Yu P, Di Prospero NA, Sapko MT, Cai T, Chen A, Melendez-Ferro M, Du F, Whetsell WO Jr, Guidetti P, Schwarcz R, Tagle DA.

Mol Cell Biol. 2004 Aug;24(16):6919-30.

31.

Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus.

Alkondon M, Pereira EF, Yu P, Arruda EZ, Almeida LE, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, Tagle DA, Albuquerque EX.

J Neurosci. 2004 May 12;24(19):4635-48.

32.

Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease.

Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang DM.

Mol Cell Neurosci. 2003 Mar;22(3):285-97.

PMID:
12691731
33.

PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains.

Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M.

Hum Mol Genet. 2002 Oct 1;11(21):2547-58.

PMID:
12354780
34.

Striatal neurochemical changes in transgenic models of Huntington's disease.

Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS.

J Neurosci Res. 2002 Jun 15;68(6):716-29.

PMID:
12111832
35.
36.

Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.

Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N.

J Neurosci. 2001 Dec 1;21(23):9112-23.

37.
38.

Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA.

Exp Neurol. 2001 Jun;169(2):340-50.

PMID:
11358447
39.
40.

Normal and mutant huntingtin: partners in crime.

Di Prospero NA, Tagle DA.

Nat Med. 2000 Nov;6(11):1208-9. No abstract available.

PMID:
11062523
41.

Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models.

Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, Brownstein MJ, Tagle DA.

Neurosci Lett. 2000 Jul 28;289(1):29-32.

PMID:
10899401
42.

Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Guidetti P, Reddy PH, Tagle DA, Schwarcz R.

Neurosci Lett. 2000 Apr 14;283(3):233-5.

PMID:
10754231
43.
45.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

46.

Recent advances in understanding the pathogenesis of Huntington's disease.

Reddy PH, Williams M, Tagle DA.

Trends Neurosci. 1999 Jun;22(6):248-55. Review.

PMID:
10354600
47.

Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays.

Hacia JG, Sun B, Hunt N, Edgemon K, Mosbrook D, Robbins C, Fodor SP, Tagle DA, Collins FS.

Genome Res. 1998 Dec;8(12):1245-58.

48.

Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO Jr, Miller G, Tagle DA.

Nat Genet. 1998 Oct;20(2):198-202.

PMID:
9771716
49.

Mapping and characterization of novel (CAG)n repeat cDNAs from adult human brain derived by the oligo capture method.

Reddy PH, Stockburger E, Gillevet P, Tagle DA.

Genomics. 1997 Dec 1;46(2):174-82.

PMID:
9417904
50.

Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways.

Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A.

Nat Genet. 1997 Dec;17(4):453-6. Erratum in: Nat Genet 1998 Mar;18(3):298.

PMID:
9398849

Supplemental Content

Loading ...
Support Center